220 related articles for article (PubMed ID: 18055335)
21. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
[TBL] [Abstract][Full Text] [Related]
22. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Ortega J; List A
Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
[TBL] [Abstract][Full Text] [Related]
24. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
25. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Stahl M; Zeidan AM
Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
[TBL] [Abstract][Full Text] [Related]
26. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
Melchert M; Kale V; List A
Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
Komrokji RS; List AF
Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
[TBL] [Abstract][Full Text] [Related]
28. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
29. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Oliva EN; Latagliata R; Laganà C; Breccia M; Galimberti S; Morabito F; Poloni A; Balleari E; Cortelezzi A; Palumbo G; Sanpaolo G; Volpe A; Specchia G; Finelli C; D'Errigo MG; Rodà F; Alati C; Alimena G; Nobile F; Aloe Spiriti MA
Leuk Lymphoma; 2013 Nov; 54(11):2458-65. PubMed ID: 23432724
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Giagounidis AA
Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
[TBL] [Abstract][Full Text] [Related]
35. [Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].
Jonášová A; Červinek L; Bělohlávková P; Čermák J; Beličková M; Rohoň P; Černá O; Hochová I; Šišková M; Kačmářová K; Janoušová E
Vnitr Lek; 2015 Dec; 61(12):1028-33. PubMed ID: 26806497
[TBL] [Abstract][Full Text] [Related]
36. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
Leitch HA; Buckstein R; Shamy A; Storring JM
Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
[TBL] [Abstract][Full Text] [Related]
37. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
[TBL] [Abstract][Full Text] [Related]
38. [MDS with deletion 5q - a distinct subtype of myelodysplastic syndromes].
Wilk CM; Goede JS
Ther Umsch; 2022; 79(2):87-91. PubMed ID: 35291851
[TBL] [Abstract][Full Text] [Related]
39. Where Does Lenalidomide Fit in Non-del(5q) MDS?
Giagounidis A
Curr Hematol Malig Rep; 2015 Sep; 10(3):303-8. PubMed ID: 26169489
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
